학술논문
"New Targets in Non–Small-Cell Lung Cancer"—RET, HER2, and KRAS.
Document Type
Article
Author
Source
American Journal of Respiratory & Critical Care Medicine; 3/15/2024, Vol. 209 Issue 6, p748-750, 3p
Subject
Language
ISSN
1073449X
Abstract
The article explores recent developments in the treatment of non-small-cell lung cancer (NSCLC) through the lens of three targeted therapies: pralsetinib for RET fusion-positive NSCLC, trastuzumab deruxtecan for HER2-mutant NSCLC, and sotorasib for NSCLC with KRAS p.G12C mutation. It provides insights into the efficacy, safety, and potential limitations of these treatments, highlighting their significance in advancing personalized medicine for lung cancer patients.